LALL
MCID: LYM138
MIFTS: 49

Lymphoblastic Leukemia, Acute, with Lymphomatous Features (LALL)

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards integrated aliases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

Name: Lymphoblastic Leukemia, Acute, with Lymphomatous Features 56 29 6
Acute Lymphoblastic Leukemia with Lymphomatous Features 71
Leukemia, Acute Lymphoblastic 56
Lymphomatous All 56
Lall 56

Characteristics:

OMIM:

56
Inheritance:
acquired specific neoplasm by autosomal recessive mechanism through somatic cell mutation


HPO:

31
lymphoblastic leukemia, acute, with lymphomatous features:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 247640
MedGen 41 C1855472
UMLS 71 C1855472

Summaries for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards based summary : Lymphoblastic Leukemia, Acute, with Lymphomatous Features, also known as acute lymphoblastic leukemia with lymphomatous features, is related to leukemia, acute lymphoblastic and t-cell acute lymphoblastic leukemia. An important gene associated with Lymphoblastic Leukemia, Acute, with Lymphomatous Features is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Prednisone and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are lymphoma and t-cell acute lymphoblastic leukemias

More information from OMIM: 247640

Related Diseases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 32.8 JAK3 JAK2 JAK1 IL7R CRLF2 ABL1
2 t-cell acute lymphoblastic leukemia 30.3 NT5C2 JAK3 JAK1 IL7R CRLF2 ABL1
3 hypereosinophilic syndrome 29.9 JAK2 FGFR1 ABL1
4 leukemia 29.9 JAK3 JAK2 JAK1 FGFR1 CRLF2 ABL1
5 adult acute lymphocytic leukemia 29.8 CRLF2 ABL1
6 leukemia, acute myeloid 28.4 JAK3 JAK2 JAK1 IL7R FGFR1 ABL1
7 leukemia, acute lymphoblastic 3 12.7
8 leukemia, acute lymphoblastic 2 12.6
9 acute leukemia 10.5
10 precursor t-cell acute lymphoblastic leukemia 10.4
11 childhood acute lymphocytic leukemia 10.3
12 thrombocythemia 3 10.2 JAK2 INSL6
13 stuttering 10.2
14 coccidiosis 10.2
15 neutropenia 10.2
16 mixed lacrimal gland cancer 10.2 JAK2 JAK1
17 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.2 JAK2 ABL1
18 acquired polycythemia 10.2 JAK2 ABL1
19 myelophthisic anemia 10.1 JAK2 ABL1
20 lymphoblastic lymphoma 10.1
21 pancytopenia 10.1
22 splenomegaly 10.1
23 jak3-deficient severe combined immunodeficiency 10.1 JAK3 JAK1
24 wernicke encephalopathy 10.1 JAK2 JAK1
25 leukemia, chronic lymphocytic 10.1
26 childhood leukemia 10.1
27 myeloid leukemia 10.1
28 alopecia universalis congenita 10.0 JAK3 JAK1
29 mixed phenotype acute leukemia 10.0 FGFR1 ABL1
30 myelodysplastic/myeloproliferative neoplasm 10.0 JAK2 ABL1
31 lymphoma 10.0
32 acute kidney failure 10.0
33 t-cell lymphoblastic leukemia/lymphoma 10.0
34 meningitis 10.0
35 47,xyy 10.0
36 leukemia, t-cell, chronic 10.0
37 b-lymphoblastic leukemia/lymphoma with iamp21 10.0 CRLF2 ABL1
38 chronic neutrophilic leukemia 10.0 JAK2 ABL1
39 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 9.9 JAK2 FGFR1 ABL1
40 bone marrow cancer 9.9 JAK2 JAK1 ABL1
41 atypical chronic myeloid leukemia 9.9 JAK2 FGFR1 ABL1
42 chronic eosinophilic leukemia 9.9 JAK2 FGFR1 ABL1
43 childhood t-cell acute lymphoblastic leukemia 9.9 IL7R ABL1
44 t-cell prolymphocytic leukemia 9.9 JAK3 JAK1 ABL1
45 prolymphocytic leukemia 9.9 JAK3 JAK1 ABL1
46 chediak-higashi syndrome 9.8
47 leukemia, chronic myeloid 9.8
48 gastric cancer 9.8
49 myelodysplastic syndrome 9.8
50 glucocorticoid resistance, generalized 9.8

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:



Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Symptoms & Phenotypes for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Human phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

31
# Description HPO Frequency HPO Source Accession
1 lymphoma 31 HP:0002665
2 t-cell acute lymphoblastic leukemias 31 HP:0006727

Symptoms via clinical synopsis from OMIM:

56
Heme:
acute lymphoblastic leukemia (all)
lymphomatous all (lall)
t-cell all

Lab:
chromosome loss of bands 9p22-p21 by deletion, unbalanced translocation, or loss of entire chromosome
loss of methylthioadenosine phosphorylase in malignant cells during relapse

Misc:
bulky disease of lymph nodes, spleen, and mediastinum

Clinical features from OMIM:

247640

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.93 ABL1 FGFR1
2 Decreased viability GR00221-A-2 9.93 ABL1 FGFR1 JAK1 JAK2
3 Decreased viability GR00221-A-3 9.93 ABL1
4 Decreased viability GR00249-S 9.93 JAK1
5 Decreased viability GR00342-S-1 9.93 ABL1
6 Decreased viability GR00342-S-2 9.93 ABL1
7 Decreased viability GR00342-S-3 9.93 ABL1
8 Decreased viability GR00386-A-1 9.93 FGFR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.78 JAK3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.78 IL7R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.78 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.78 IL7R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.78 IL7R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.78 JAK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.78 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.78 IL7R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.78 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.78 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.78 IL7R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.78 IL7R
23 Increased shRNA abundance (Z-score > 2) GR00366-A-20 9.78 JAK3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.78 ABL1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.78 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.78 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.78 ABL1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 ABL1 FGFR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 ABL1 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.78 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.78 JAK3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.78 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 ABL1 JAK3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.78 JAK3
35 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.26 FGFR1 JAK3
36 Decreased viability in CMK cells GR00105-A-0 8.96 JAK1 JAK3

MGI Mouse Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.87 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK2
2 endocrine/exocrine gland MP:0005379 9.86 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK1
3 hematopoietic system MP:0005397 9.76 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2
4 immune system MP:0005387 9.5 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2
5 normal MP:0002873 9.1 ABL1 FGFR1 IL7R JAK1 JAK2 NT5C2

Drugs & Therapeutics for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Drugs for Lymphoblastic Leukemia, Acute, with Lymphomatous Features (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mercaptopurine Approved Phase 4 50-44-2 667490
3
asparaginase Phase 4
4
Pegaspargase Approved, Investigational Phase 3 130167-69-0
5
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
8
Teniposide Approved Phase 3 29767-20-2 34698
9
Idarubicin Approved Phase 3 58957-92-9 42890
10
Blinatumomab Approved, Investigational Phase 3 853426-35-4
11
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
16 Etoposide phosphate Phase 3
17 topoisomerase I inhibitors Phase 3
18 Antibodies, Bispecific Phase 3
19 Imatinib Mesylate Phase 3 220127-57-1 123596
20 Protein Kinase Inhibitors Phase 3
21 Gastrointestinal Agents Phase 3
22 Hormones Phase 3
23 Antineoplastic Agents, Hormonal Phase 3
24 Tubulin Modulators Phase 3
25 Hormone Antagonists Phase 3
26 Antiemetics Phase 3
27 glucocorticoids Phase 3
28
Liposomal doxorubicin Phase 3 31703
29 Antimitotic Agents Phase 3
30 Anti-Inflammatory Agents Phase 3
31
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
32
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
33
leucovorin Approved Phase 2 58-05-9 6006 143
34
Micafungin Approved, Investigational Phase 2 235114-32-6 477468 3081921
35
tannic acid Approved Phase 1, Phase 2 1401-55-4
36
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
37
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
38
Mesna Approved, Investigational Phase 2 3375-50-6 598
39
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
41
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
43 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
44
Daunorubicin Approved Phase 2 20830-81-3 30323
45
Thioguanine Approved Phase 2 154-42-7 2723601
46
Palbociclib Approved, Investigational Phase 1, Phase 2 571190-30-2 5005498 11431660 5330286
47
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Melphalan Approved Phase 2 148-82-3 460612 4053
50
Thiotepa Approved, Investigational Phase 2 52-24-4 5453

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
2 An Open-label Multi-center Study of Imatinib and Nilotinib in CAMN107ECN02 On-treatment Patients With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase After the End of CAMN107ECN02 Core Study Completed NCT02272777 Phase 3 Imatinib;Nilotinib
3 A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
4 A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16) Completed NCT00187083 Phase 3 Topotecan, dexamethasone, vincristine;E. coli Asparaginase, PEG-L-asparaginase;erwinia asparaginase;fludarabine, methotrexate, mercaptopurine;idarubicin, etoposide, cytarbine, teniposide
5 Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL Active, not recruiting NCT02393859 Phase 3 Blinatumomab;Conventional Consolidation Chemotherapy
6 ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (1-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) Not yet recruiting NCT04307576 Phase 3 Omitted Doxorubicin;Omitted Vincristine+Dexamethasone pulses;Inotuzumab Ozogamicin+Standard Maintenance Therapy;Imatinib
7 A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY Unknown status NCT01914484 Phase 1, Phase 2 Nilotinib;Ruxolitinib
8 A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies Unknown status NCT01092026 Phase 1, Phase 2
9 A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL Completed NCT00384228 Phase 1, Phase 2 Nilotinib
10 A Phase II Study Of CCI-779 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase Completed NCT00084916 Phase 2 temsirolimus
11 A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT01244906 Phase 2
12 HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY Completed NCT01795378 Phase 1, Phase 2
13 A Study of a Reduced-Intensity Conditioning Regimen With Treosulfan and Fludarabine for Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Leukemia Completed NCT00253513 Phase 1, Phase 2 fludarabine;treosulfan
14 Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders Completed NCT00028730 Phase 2 cyclophosphamide;fludarabine phosphate;thiotepa
15 A Phase II Multicentre Open-label Study on Allogeneic Stem Cell Transplantation From Unrelated, Cord-blood and Family Haploidentical Donors in Patients With Active Acute Leukemia Completed NCT01814488 Phase 2
16 An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies Completed NCT02420873 Phase 2 Lorvotuzumab Mertansine (IMGN901)
17 Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine Completed NCT00001873 Phase 2
18 Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Irradiated Donor Lymphocytes on Chimerism Completed NCT00061581 Phase 2
19 Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Completed NCT00056966 Phase 1, Phase 2 ANTI-CD45;CAMPATH-1H;FK506;Fludarabine
20 Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Role of Preparative Regimen and T Cell Dose in Graft Rejection and GVHD Completed NCT00353860 Phase 2
21 Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia Completed NCT00671658 Phase 2 Rituximab;Cyclophosphamide (CTX);Doxorubicin;Vincristine;Dexamethasone;Methotrexate (MTX);Cytarabine;G-CSF;Mesna;Pegylated asparaginase;Pegfilgrastim;Solumedrol
22 Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
23 Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Recruiting NCT02795520 Phase 1, Phase 2 OTS167IV
24 Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia Recruiting NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
25 Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1 Recruiting NCT02310243 Phase 1, Phase 2 Palbociclib
26 Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial. Recruiting NCT04232241 Phase 2 Allogeneic Stem Cell Transplantation
27 A Phase 1, Non-randomized, Open-Label/ Phase 2 Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells)Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies Patients With Hematologic Malignancies Recruiting NCT02743351 Phase 1, Phase 2
28 CRSPA: Phase I/II Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Recruiting NCT04195347 Phase 1, Phase 2 CM4620
29 A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Recruiting NCT03128034 Phase 1, Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
30 Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome Recruiting NCT00357565 Phase 2 busulfan;cyclosporine;fludarabine phosphate;melphalan;mycophenolate mofetil
31 Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor Active, not recruiting NCT01865617 Phase 1, Phase 2
32 Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies Active, not recruiting NCT01690520 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
33 Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies Terminated NCT01622556 Phase 2 Fludarabine;Busulfan;Thymoglobulin
34 Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia Terminated NCT02935543 Phase 2
35 Bridging Study: A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia and Minimal Residual Disease Terminated NCT02349178 Phase 2 Clofarabine;Cyclophosphamide;Etoposide
36 A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25) Terminated NCT00295880 Phase 1, Phase 2
37 Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation Terminated NCT00617929 Phase 2 clofarabine
38 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
39 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors Terminated NCT01532635 Phase 2 Cyclophosphamide (CY);Tacrolimus;Mycophenolate Mofetil (MMF)
40 Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases Terminated NCT00579111 Phase 1, Phase 2 Campath;Busulfan;Fludarabine;FK-506
41 A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia Completed NCT00964873 Phase 1 STA-9090 (ganetespib)
42 A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Completed NCT01700751 Phase 1 brentuximab vedotin
43 A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies Completed NCT01607892 Phase 1 KPT-330
44 Phase I Study of PS-341 in Acute Myeloid Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase Completed NCT00005064 Phase 1 bortezomib
45 Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS Completed NCT00374933 Phase 1 Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI;"Prophylactic" delayed ADLI;"Prophylactic" delayed activated donor lymphocyte infusion
46 A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia Completed NCT01137747 Phase 1 Carfilzomib
47 A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL Completed NCT01077544 Phase 1 Nilotinib
48 Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00107354 Phase 1 cytarabine;etoposide;mitoxantrone hydrochloride
49 A Phase I And Pharmacological Trial Of 17-Allylamino -17-demethoxygeldanamycin (17-AAG) And Cytarabine In Refractory Leukemia And Myelodysplastic Syndrome Completed NCT00098423 Phase 1 tanespimycin;cytarabine
50 A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib

Search NIH Clinical Center for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic Tests for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic tests related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

# Genetic test Affiliating Genes
1 Lymphoblastic Leukemia, Acute, with Lymphomatous Features 29

Anatomical Context for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards organs/tissues related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

40
Myeloid, T Cells, Bone Marrow, Bone, Lymph Node, Spleen, Testes

Publications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Articles related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

(show all 20)
# Title Authors PMID Year
1
Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. 56
3925340 1985
2
Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. 56
6785752 1981
3
Erratum: This Article Corrects: "Assessment of Physician Well-being, Part Two: Beyond Burnout". 61
32421526 2020
4
Identification of non-alkaloid natural compounds of Angelica purpurascens (Avé-Lall.) Gilli. (Apiaceae) with cholinesterase and carbonic anhydrase inhibition potential. 61
31920428 2020
5
Proproliferative function of adaptor protein GRB10 in prostate carcinoma. 61
30379590 2019
6
Adrenaline can restart the heart, but is no good for the brain. 61
30833377 2019
7
Re-evaluation of endogenous development of Eimeria bareillyi Gill, Chhabra and Lall, 1963 in water buffalo (Bubalus bubalis). 61
29692286 2018
8
Physiologic regulation of heart rate and blood pressure involves connexin 36-containing gap junctions. 61
28533325 2017
9
Ischemic Heart Disease Mortality and Long-Term Exposure to Source-Related Components of U.S. Fine Particle Air Pollution. 61
26629599 2016
10
Ultrastructure and elemental analysis of Hypoxis hemerocallidea: a multipurpose medicinal plant. 61
25392578 2014
11
Comparison of methods for online measurement of diesel particulate matter. 61
22568856 2012
12
Investigation of Aerosol Surface Area Estimation from Number and Mass Concentration Measurements: Particle Density Effect. 61
26526560 2012
13
Authentication of Angelica anomala Avé-Lall cultivars through DNA barcodes. 61
22397381 2012
14
Bayesian sample size determination for the accurate identification of the bacterial subtypes. 61
20088071 2009
15
Astaxanthin binding to solubilized muscle proteins of Atlantic salmon (Salmo salar L.), haddock (Melanogrammus aeglefinus L.) and Atlantic halibut (Hippoglossus hippoglossus L.). 61
16781177 2006
16
Effect of exposure of foetal red cells to hydrogen peroxide. 61
8119762 1993
17
[Luminescence of the tissues of the (Angelica anomala Ave-Lall.) root and localization of coumarins in them]. 61
5149844 1971
18
[New coumarins isolated from the roots of Angelica anomala Lall. and Angelica cartilaginomarginata (Makino) Nakai (Umbelliferae)]. 61
5627435 1967
19
The constitution of anomalin, a new coumarin isolated from the root of Angelica anomala Lall. (umbelliferae). 61
5920524 1966
20
[Pharmacognostical studies on umbelliferous plants. XX. Studies on Chinese drug "bvaku-shi". 5. On the coumarins of the roots of Angelica formosana Boiss. and A. anomala Lall]. 61
13960930 1963

Variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

ClinVar genetic disease variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

6 (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 INSL6 , JAK2 NM_004972.3(JAK2):c.2048G>C (p.Arg683Thr)SNV Pathogenic 375952 rs1057519722 9:5078361-5078361 9:5078361-5078361
2 INSL6 , JAK2 NM_004972.3(JAK2):c.2049A>C (p.Arg683Ser)SNV Pathogenic 375953 rs1057519723 9:5078362-5078362 9:5078362-5078362
3 INSL6 , JAK2 NM_004972.3(JAK2):c.2049A>T (p.Arg683Ser)SNV Pathogenic 375954 rs1057519723 9:5078362-5078362 9:5078362-5078362
4 CRLF2 NM_022148.4(CRLF2):c.695T>G (p.Phe232Cys)SNV Pathogenic 376003 rs1057519743 X:1314966-1314966 X:1196852-1196852
5 ABL1 NM_005157.6(ABL1):c.944C>T (p.Thr315Ile)SNV Pathogenic/Likely pathogenic 12624 rs121913459 9:133748283-133748283 9:130872896-130872896
6 ABL1 NM_005157.6(ABL1):c.757T>C (p.Tyr253His)SNV Pathogenic/Likely pathogenic 12627 rs121913461 9:133738357-133738357 9:130862970-130862970
7 FGFR1 NM_023110.2(FGFR1):c.1966A>G (p.Lys656Glu)SNV Pathogenic/Likely pathogenic 224897 rs869320694 8:38272308-38272308 8:38414790-38414790
8 INSL6 , JAK2 NM_004972.3(JAK2):c.2047A>G (p.Arg683Gly)SNV Pathogenic/Likely pathogenic 375951 rs1057519721 9:5078360-5078360 9:5078360-5078360
9 FGFR1 NM_015850.4(FGFR1):c.1962G>C (p.Lys654Asn)SNV Likely pathogenic 376428 rs1057519897 8:38272306-38272306 8:38414788-38414788
10 JAK1 NM_002227.4(JAK1):c.1901C>A (p.Ala634Asp)SNV Likely pathogenic 225075 rs869312953 1:65312418-65312418 1:64846735-64846735
11 JAK1 NM_002227.4(JAK1):c.1972G>T (p.Val658Phe)SNV Likely pathogenic 376030 rs1057519753 1:65312347-65312347 1:64846664-64846664
12 IL7R NM_002185.5(IL7R):c.553A>T (p.Ser185Cys)SNV Likely pathogenic 376098 rs1057519759 5:35873597-35873597 5:35873495-35873495
13 JAK1 NM_002227.4(JAK1):c.1937C>T (p.Ser646Phe)SNV Likely pathogenic 376099 rs151047872 1:65312382-65312382 1:64846699-64846699
14 JAK3 NM_000215.3(JAK3):c.2164G>A (p.Val722Ile)SNV Benign/Likely benign 134573 rs3213409 19:17945696-17945696 19:17834887-17834887
15 JAK3 NM_000215.3(JAK3):c.394C>A (p.Pro132Thr)SNV Benign/Likely benign 134580 rs3212723 19:17954215-17954215 19:17843406-17843406
16 NT5C2 NM_012229.4(NT5C2):c.1075A>C (p.Lys359Gln)SNV not provided 376350 rs1057519867 10:104852980-104852980 10:103093223-103093223

Expression for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search GEO for disease gene expression data for Lymphoblastic Leukemia, Acute, with Lymphomatous Features.

Pathways for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Pathways related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 JAK3 JAK2 JAK1 IL7R FGFR1 ABL1
2
Show member pathways
13.18 JAK3 JAK2 JAK1 IL7R FGFR1
3
Show member pathways
13.14 JAK3 JAK2 JAK1 IL7R FGFR1
4
Show member pathways
12.74 JAK3 JAK2 JAK1 IL7R FGFR1
5
Show member pathways
12.66 JAK3 JAK2 JAK1 FGFR1
6
Show member pathways
12.55 JAK3 JAK2 JAK1 IL7R
7 12.52 JAK3 JAK2 JAK1 IL7R FGFR1 ABL1
8
Show member pathways
12.29 JAK2 JAK1 FGFR1 ABL1
9
Show member pathways
12.22 JAK3 JAK2 JAK1
10
Show member pathways
12.21 JAK3 JAK2 JAK1
11
Show member pathways
12.15 JAK3 JAK2 JAK1
12
Show member pathways
12.11 JAK3 JAK2 JAK1
13
Show member pathways
12.09 JAK3 JAK2 JAK1 FGFR1
14
Show member pathways
12.02 JAK3 JAK2 JAK1
15 12 JAK2 JAK1 ABL1
16
Show member pathways
11.95 JAK3 JAK2 JAK1
17 11.93 JAK2 FGFR1 ABL1
18 11.89 JAK3 JAK2 JAK1 FGFR1
19
Show member pathways
11.87 JAK3 JAK2 JAK1
20 11.79 JAK3 JAK2 JAK1
21
Show member pathways
11.79 JAK3 JAK2 JAK1 IL7R
22
Show member pathways
11.69 JAK3 JAK2 JAK1
23
Show member pathways
11.68 JAK2 JAK1
24
Show member pathways
11.67 JAK3 JAK2 JAK1
25
Show member pathways
11.5 JAK3 JAK2 JAK1 IL7R CRLF2 ABL1
26 11.45 JAK3 JAK2 JAK1
27 11.32 JAK2 JAK1
28
Show member pathways
11.29 JAK3 JAK1
29
Show member pathways
11.29 JAK2 JAK1
30
Show member pathways
11.28 JAK3 JAK1 IL7R
31 11.24 JAK3 IL7R
32 11.21 JAK2 JAK1
33 11.13 JAK2 JAK1 IL7R CRLF2
34 11.04 JAK3 JAK2 JAK1
35 10.99 JAK3 JAK1 IL7R
36 10.92 JAK3 JAK2 JAK1 CRLF2
37 10.88 JAK2 JAK1

GO Terms for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Cellular components related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endomembrane system GO:0012505 8.8 JAK3 JAK2 JAK1

Biological processes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 JAK2 IL7R FGFR1 CRLF2
2 regulation of apoptotic process GO:0042981 9.8 JAK3 JAK2 ABL1
3 protein autophosphorylation GO:0046777 9.77 JAK2 FGFR1 ABL1
4 phosphorylation GO:0016310 9.77 JAK3 JAK2 JAK1 FGFR1 ABL1
5 cytokine-mediated signaling pathway GO:0019221 9.71 JAK3 JAK2 JAK1 CRLF2
6 protein phosphorylation GO:0006468 9.65 JAK3 JAK2 JAK1 FGFR1 ABL1
7 positive regulation of cell differentiation GO:0045597 9.64 JAK2 FGFR1
8 erythrocyte differentiation GO:0030218 9.64 JAK3 JAK2
9 interleukin-12-mediated signaling pathway GO:0035722 9.63 JAK2 JAK1
10 B cell proliferation GO:0042100 9.62 IL7R ABL1
11 platelet-derived growth factor receptor signaling pathway GO:0048008 9.62 JAK2 ABL1
12 MAPK cascade GO:0000165 9.62 JAK3 JAK2 JAK1 FGFR1
13 response to antibiotic GO:0046677 9.61 JAK2 JAK1
14 interleukin-6-mediated signaling pathway GO:0070102 9.59 JAK2 JAK1
15 negative regulation of cell-cell adhesion GO:0022408 9.58 JAK2 ABL1
16 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 JAK3 JAK2
17 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.57 JAK2 JAK1
18 interleukin-15-mediated signaling pathway GO:0035723 9.56 JAK3 JAK1
19 interleukin-35-mediated signaling pathway GO:0070757 9.55 JAK2 JAK1
20 interleukin-27-mediated signaling pathway GO:0070106 9.54 JAK2 JAK1
21 interleukin-2-mediated signaling pathway GO:0038110 9.52 JAK3 JAK1
22 regulation of JAK-STAT cascade GO:0046425 9.51 JAK3 JAK2
23 interleukin-9-mediated signaling pathway GO:0038113 9.49 JAK3 JAK1
24 tyrosine phosphorylation of STAT protein GO:0007260 9.48 JAK3 JAK2
25 interleukin-21-mediated signaling pathway GO:0038114 9.46 JAK3 JAK1
26 enzyme linked receptor protein signaling pathway GO:0007167 9.43 JAK3 JAK2
27 peptidyl-tyrosine phosphorylation GO:0018108 9.35 JAK3 JAK2 JAK1 FGFR1 ABL1
28 positive regulation of STAT cascade GO:1904894 9.16 IL7R CRLF2
29 interleukin-7-mediated signaling pathway GO:0038111 8.92 JAK3 JAK1 IL7R CRLF2

Molecular functions related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.88 NT5C2 JAK3 JAK2 JAK1 FGFR1 ABL1
2 ATP binding GO:0005524 9.83 JAK3 JAK2 JAK1 FGFR1 ABL1
3 kinase activity GO:0016301 9.72 JAK3 JAK2 JAK1 FGFR1 ABL1
4 protein kinase activity GO:0004672 9.65 JAK3 JAK2 JAK1 FGFR1 ABL1
5 growth hormone receptor binding GO:0005131 9.37 JAK2 JAK1
6 SH2 domain binding GO:0042169 9.33 JAK2 FGFR1 ABL1
7 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.26 JAK3 JAK2 JAK1 ABL1
8 protein tyrosine kinase activity GO:0004713 9.02 JAK3 JAK2 JAK1 FGFR1 ABL1

Sources for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....